Search for: "PFIZER"
Results 1641 - 1660
of 4,632
Sort by Relevance
|
Sort by Date
1 Nov 2014, 12:47 pm
Sleet in Pfizer Inc., et al. v. [read post]
31 Oct 2014, 10:39 pm
Recently, NOACs have hit the market with FDA approval and are earning record profits for their respective manufacturers (Boehringer Ingelheim, Johnson & Johnson and Pfizer/Bristol Myers Squibb). [read post]
30 Oct 2014, 6:50 am
Pfizer, Inc., 2014 U.S. [read post]
29 Oct 2014, 1:44 pm
The Food and Drug Administration says it cleared Pfizer’s Trumenba to prevent a subtype of Meningococcal disease in people ages 10 to 25. [read post]
25 Oct 2014, 9:01 pm
Category: Claim Construction By: John Kirkpatrick, Contributor TitleHill-Rom Serv., Inc. v. [read post]
21 Oct 2014, 9:59 pm
By Andrew Williams -- Anyone that has been monitoring the outcome of district court cases recently will be aware of the perils of not including sufficient information, or not timely supplementing, preliminary infringement or invalidity contentions required by many local patent rules. [read post]
21 Oct 2014, 9:03 am
A number of Amici supported the petition, including BIO, Pfizer, Eli Lilly, PhRMA, IPO, and Merck. [read post]
20 Oct 2014, 11:55 am
The party host, his out-of-town parents, the other partygoers, Xanax manufacturer Pfizer and the looted pharmacy were all responsible, naturally. [read post]
16 Oct 2014, 6:48 am
FDA Review Panel Recommends Leaving Black Box Warnings on Chantix The FDA is set to review evidence submitted by Pfizer in their request to remove serious warnings from their anti-smoking drug, Chantix, which suggest that the drug can trigger depression and suicidal thoughts, among other side effects. [read post]
15 Oct 2014, 7:42 am
” Pfizer denies all allegations. [read post]
10 Oct 2014, 11:19 am
(LinkedIn Jobs.)Prior post: Pfizer Agrees to Create Ombuds Program for Employees; Court Approves Settlement Creating Ombuds Program for Pfizer; Ombuds to Address New Jersey Association of Professional Mediators; APM Marketplace: "Office Disputes Get a New Referee". [read post]
10 Oct 2014, 7:28 am
Reuters reports that according to a review conducted by Reuters of lawsuits filed in Federal court, there are now nearly 1,000 lawsuits filed against Pfizer by women alleging that they developed type 2 diabetes (T2D) after taking its anti-cholesterol medication Lipitor (atorvastatin calcium). [read post]
9 Oct 2014, 7:33 am
Even as these consumer advocacy groups call for stronger labels, Pfizer […] [read post]
9 Oct 2014, 6:58 am
My former company, Pfizer, has used tables of this type, and has received may compliments on it from investors and others. [read post]
7 Oct 2014, 7:23 am
Rules of the Bar,” NY Times, http://bit.ly/8i2As @ptolawyer Google has yet to appease stakeholders concerned with privacy guarantees in copyright debate:http://bit.ly/4crVS @VBalasubramani ‘Viva Viagra’ Missile Infringed on Pfizer trademarks [CNS] http://bit.ly/VCn8p //sounds like a sketchy ruling (this led to my post here – should have been credited!) [read post]
7 Oct 2014, 7:15 am
The Partnership for American Innovation (PAI), which is comprised of Apple, DuPont, Ford, GE, IBM, Microsoft and Pfizer, recently submitted comments responsive to a request for public information published in the Federal Register. [read post]
3 Oct 2014, 10:46 am
Until we reform our system, a growing number of U.S. businesses are going to follow Burger King, Pfizer and others, who, in the absence of action from Washington, are taking matters into their own hands to reduce their tax burdens. [read post]
30 Sep 2014, 9:30 am
We’ve written about how Abbott Laboratories, Eisai and Pfizer used smarmy, anticompetitive practices to protect the profits for their brand-name drugs. [read post]
26 Sep 2014, 7:18 am
With that, I present Samuel Thompson's New Inversions, the 'Joe Frazier Left Hook,' the IRS Notice, and Pfizer: Abstract: This article discusses the “New Inversions” many U.S. firms are engaging in, as illustrated... [read post]
19 Sep 2014, 9:29 pm
Dianna DeVore of Oblon, Spivak, McClelland, Maier & Neustadt, LLP; Matthew Pugmire of Pfizer, Inc.; and Michael Samardzija of Dentons US LLP examine the alternative of using trade secrets to protect intellectual property in the life sciences. [read post]
